Sodelglitazar

DB16332InvestigationalSmall molecule

Sodelglitazar is under investigation in clinical trial NCT00196989 (Study in People With Type 2 Diabetes).

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptors
Curator reviewed
Formula / weight: C₂₃H₂₁F₄NO₃S₂ · 499.54 g/mol (avg)
Code names: GW-677954

Resolves to

Compound

Structure

InChIKeyZUGQWAYOWCBWGM-UHFFFAOYSA-NSMILESCC1=C(CSC2=CC=C(OC(C)(C)C(O)=O)C(C)=C2)SC(=N1)C1=CC=C(C=C1F)C(F)(F)F

Targets

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sodelglitazar, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.